1. Home
  2. ENVB vs GTBP Comparison

ENVB vs GTBP Comparison

Compare ENVB & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enveric Biosciences Inc.

ENVB

Enveric Biosciences Inc.

SELL

Current Price

$10.15

Market Cap

3.0M

Sector

Health Care

ML Signal

SELL

Logo GT Biopharma Inc.

GTBP

GT Biopharma Inc.

HOLD

Current Price

$0.68

Market Cap

2.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENVB
GTBP
Founded
1994
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
2.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ENVB
GTBP
Price
$10.15
$0.68
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$120.00
N/A
AVG Volume (30 Days)
1.8M
1.5M
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.88
$0.54
52 Week High
$96.30
$4.10

Technical Indicators

Market Signals
Indicator
ENVB
GTBP
Relative Strength Index (RSI) 77.38 47.14
Support Level $5.75 $0.58
Resistance Level $6.99 $0.82
Average True Range (ATR) 0.86 0.07
MACD 0.14 -0.01
Stochastic Oscillator 58.23 33.00

Price Performance

Historical Comparison
ENVB
GTBP

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: